The gene-editing beyond CRISPR market is anticipated to grow at an annualized rate of 18%, claims Roots Analysis

With the approval of HUMULIN®, the first genetically modified drug, scientific community has made significant progress in developing gene edited therapies based on programmable nucleases, such as ZFNs, TALENs, EMNs and CRISPR.

For additional details, please visit
https://www.rootsanalysis.com/reports/gene-editing-market.html
 

comments (0)

45 more from jameshebrew